AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
relebactam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-lactamase inhibitors | 5342 | 1174018-99-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
RECARBRIO is a combination of imipenem/cilastatin and relebactam. Imipenem is a penem antibacterial drug, cilastatin sodium is a renal dehydropeptidase inhibitor, and relebactam is a beta lactamase inhibitor. Cilastatin limits the renal metabolism of imipenem and does not have antibacterial activity. The bactericidal activity of imipenem results from binding to PBP 2 and PBP 1B in Enterobacteriaceae and Pseudomonas aeruginosa and the subsequent inhibition of penicillin binding proteins (PBPs). Inhibition of PBPs leads to the disruption of bacterial cell wall synthesis. Imipenem is stable in the presence of some beta lactamases. Relebactam has no intrinsic antibacterial activity. Relebactam protects imipenem from degradation by certain serine beta lactamases such as Sulhydryl Variable (SHV), Temoneira (TEM), Cefotaximase-Munich 13 Reference ID: 4462927 (CTX-M), Enterobacter cloacae P99 (P99), Pseudomonas-derived cephalosporinase (PDC), and Klebsiella-pneumoniae carbapenemase (KPC)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 70 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,PDK1,PDK2,PRKDC,TEK | 15 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2D,CDK4,CDK9,DYRK1B,GRK2,MAPK7,SIK2,STK33,SYK,TEK | 12 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 23, 2021 | PMDA | MSD K.K. | |
| June 16, 2019 | FDA | MSD MERCK CO |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DH56 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D065093 | beta-Lactamase Inhibitors |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
J01DH Carbapenems 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection caused by Pseudomonas aeruginosa strain resistant to carbapenem antimicrobial drugs | indication | 11218009 | |
| Pyelonephritis | indication | 45816000 | DOID:11400 |
| Urinary tract infectious disease | indication | 68566005 | |
| Infection caused by Escherichia coli strain resistant to carbapenem antimicrobial drugs | indication | 71057007 | |
| Infection caused by Serratia spp resistant to carbapenem antimicrobial drugs | indication | 71120004 | |
| Intestinal infection due to Pseudomonas | indication | 82930004 | |
| Intestinal infection due to E. coli | indication | 111839008 | |
| Infectious disease of abdomen | indication | 128070006 | |
| Pseudomonas gastrointestinal tract infection | indication | 266078006 | |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Pseudomonas urinary tract infection | indication | 301013004 | |
| Infection caused by Enterococcus spp resistant to carbapenem antimicrobial drugs | indication | 406574007 | |
| Gastrointestinal infection caused by Klebsiella aerogenes | indication | 421429008 | |
| Infection caused by Klebsiella spp resistant to carbapenem antimicrobial drugs | indication | 721756002 | |
| Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs | indication | 840588006 | |
| Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs | indication | 1137353009 | |
| Urinary tract infection caused by Klebsiella | indication | ||
| Complicated Genitourinary Tract Infection | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.53 | acidic |
| pKa2 | 9.75 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | 8487093 | March 21, 2033 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI) |
| EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | 8487093 | March 21, 2033 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI) |
| EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | 8487093 | March 21, 2033 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | July 16, 2024 | NEW CHEMICAL ENTITY |
| EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | Dec. 9, 2028 | NEW PATIENT POPULATION |
| EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | RECARBRIO | MSD MERCK CO | N212819 | July 16, 2019 | RX | POWDER | INTRAVENOUS | July 16, 2029 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.40 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.33 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.64 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.59 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Beta-lactamase | Enzyme | INHIBITOR | IC50 | 6.04 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Beta-lactamase | Enzyme | IC50 | 6.33 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| Y1MYA2UHFL | UNII |
| 4039070 | VANDF |
| C4317244 | UMLSCUI |
| CHEBI:755288 | CHEBI |
| CHEMBL3301605 | ChEMBL_ID |
| 44129647 | PUBCHEM_CID |
| DB12377 | DRUGBANK_ID |
| D11621 | KEGG_DRUG |
| C568736 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10852 | IUPHAR_LIGAND_ID |
| C000633884 | MESH_SUPPLEMENTAL_RECORD_UI |
| 789066008 | SNOMEDCT_US |
| 321713 | MMSL |
| 37333 | MMSL |
| d09357 | MMSL |
| 018062 | NDDF |
| 1174020-13-3 | SECONDARY_CAS_RN |
| 2184137 | RXNORM |
Pharmaceutical products:
None